Maltofer Fol, 30 pcs.

Maltofer® Fol contains iron in the form of a polymaltose complex of iron (III) hydroxide. This macromolecular complex is stable and does not release iron in the form of free ions in the gastrointestinal tract.

The structure of Maltofer® Fol is similar to the natural iron compound ferritin. Due to this similarity, iron (III) is transported from the intestine into the blood by active transport. It is this property that explains the impossibility of overdose of the drug in contrast to simple iron salts, the absorption of which occurs by a concentration gradient.

The absorbed iron is bound to ferritin and stored in the body, mainly in the liver. It is then incorporated into hemoglobin in the bone marrow. Iron, which is part of the polymaltose complex of iron (III) hydroxide, does not have pro-oxidant properties, unlike simple iron salts.

There is a correlation between the severity of iron deficiency and the level of iron absorption (the greater the severity of iron deficiency, the better the absorption). The most active absorption process occurs in the duodenum and small intestine.

Folic acid, a B vitamin, stimulates erythropoiesis and is involved in the synthesis of amino acids, nucleic acids, purines, pyrimidines and choline metabolism.

Maltofer® Fol in a dosage form of chewable tablets does not cause staining of teeth enamel.

Indications

Treatment of latent and clinically expressed iron deficiency (iron deficiency anemia); prevention of iron and folic acid deficiency (including before, during and after pregnancy, during lactation).

Composition

Active substances:

Iron (III) hydroxide polymaltosate (equivalent to 100 mg of iron); folic acid 0.35 mg;

Supplements:

Dextrates;

MacroGol 6000;

Talc purified;

Sodium cyclamate;

vanillin;

cocoa powder;

chocolate flavoring;

MCC;

How to take, the dosage

Ingestion.

Take with or immediately after a meal, chewed or swallowed whole.

The dosage of the drug and the duration of therapy depend on the severity of the iron deficiency. The daily dose can be taken once a day.

The treatment of clinically expressed iron deficiency (iron deficiency anemia): 1 tablet 1-3 times a day for 3-5 months until normalization of blood hemoglobin level. After this time, the drug should be continued for several more months in order to restore the iron reserves in the body (1 tablet a day).

Pregnant women should take 1 tablet of Maltofer® Fol 2-3 times a day until hemoglobin normalization. Then the therapy should be continued in dosage of 1 tablet a day at least until childbirth (for restoration of iron reserves).

For therapy of latent iron deficiency and prevention of iron and folic acid deficiency, patients should take 1 tablet of the drug daily.

The duration of treatment of clinically expressed iron deficiency (iron deficiency anemia) is 3-5 months until normalization of hemoglobin level.

Thereafter, the drug should be continued in the dosage for the treatment of latent iron deficiency for several more months, and for pregnant women, at least until childbirth (to restore iron reserves).

The duration of treatment of latent iron deficiency is 1-2 months.

In cases of clinically pronounced iron deficiency, normalization of hemoglobin levels and replenishment of iron reserves do not occur until 2-3 months after the start of treatment.

Special Instructions

One tablet of Maltofer® Fol contains 0.04 IU, which should be taken into account when prescribing to patients with diabetes.

Contraindications

Side effects

Very rare (≥0.001%,

Possible dark stool staining due to excretion of unabsorbed iron (not clinically relevant).

Pregnancy use

In controlled trials in pregnant women in the second and third trimesters of pregnancy, no adverse effects of the drug on the mother or fetus have been observed.

There are no data on undesirable effects of the drug on the fetus during the first trimester of pregnancy.